- Trials with a EudraCT protocol (512)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
512 result(s) found for: Ovarian Carcinoma.
Displaying page 1 of 26.
EudraCT Number: 2006-004484-54 | Sponsor Protocol Number: IP-CAT-OC-02 | Start Date*: 2007-08-30 | ||||||||||||||||||||||||||
Sponsor Name:Fresenius Biotech GmbH | ||||||||||||||||||||||||||||
Full Title: Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer | ||||||||||||||||||||||||||||
Medical condition: Epithelial Ovarian Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001506-25 | Sponsor Protocol Number: NN028-1802 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||||||||||||
Full Title: An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Stand... | |||||||||||||||||||||||
Medical condition: advanced epithelial Ovarian Cancer stage IIB-IV | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001724-40 | Sponsor Protocol Number: MITO-6 | Start Date*: 2005-10-18 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE | |||||||||||||
Full Title: Phase II study with capecitabine as monotherapy in the treatment of platinum resistant or refractory ovarian cancer | |||||||||||||
Medical condition: Cytologic or histologic diagnosis of relapsed ovarian cancer, refractory or resistant to platinum salts. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001661-32 | Sponsor Protocol Number: VeTo | Start Date*: 2012-07-05 | |||||||||||||||||||||
Sponsor Name:Vejle Hospital, Dept. of Oncology | |||||||||||||||||||||||
Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status | |||||||||||||||||||||||
Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004429-41 | Sponsor Protocol Number: BAY43-9006/12007 | Start Date*: 2008-10-03 | |||||||||||||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||||||||||||
Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ... | |||||||||||||||||||||||
Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005725-64 | Sponsor Protocol Number: CAGEM | Start Date*: 2006-01-20 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | |||||||||||||
Full Title: PHASE II CLINICAL AND PHARMACOKINETIC STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ADVANCED OVARIAN CARCINOMA | |||||||||||||
Medical condition: OVARIAN ADENOCARCINOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002014-22 | Sponsor Protocol Number: ONK-MAP/AZD2281-01 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Országos Onkológiai Intézet | |||||||||||||
Full Title: An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer | |||||||||||||
Medical condition: advanced ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023457-11 | Sponsor Protocol Number: S52798 | Start Date*: 2011-02-15 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UZ Leuven | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: advanced/recurrent ovarian and endometrial cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000366-36 | Sponsor Protocol Number: TLK286.3025 | Start Date*: 2006-06-07 | |||||||||||
Sponsor Name:Telik, Inc. | |||||||||||||
Full Title: Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory ... | |||||||||||||
Medical condition: platinum refractory or resistant ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005091-36 | Sponsor Protocol Number: 2020-005091-36 | Start Date*: 2021-08-30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Stichting Catharina Hospital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Ovarian cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007013-20 | Sponsor Protocol Number: MK-0683-080 (P2135) | Start Date*: 2007-02-23 | |||||||||||
Sponsor Name:Onkologisk afdeling R and the Unit for Experimental Chemotherapy | |||||||||||||
Full Title: A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancer | |||||||||||||
Medical condition: Advanced, recurrent epithelial ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002116-10 | Sponsor Protocol Number: 40/2006/O/Sper | Start Date*: 2006-05-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Carboplatin Gemcitabine as second line treatment in platinum sensitive advanced ovarian cancer phase II study on a new schedule. | |||||||||||||
Medical condition: Ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023124-24 | Sponsor Protocol Number: LUMCCHIP | Start Date*: 2011-03-02 | |||||||||||
Sponsor Name:Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
Full Title: Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. ... | |||||||||||||
Medical condition: Recurrent platinum resistant, p53 positive ovarian cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000126-31 | Sponsor Protocol Number: 1401 | Start Date*: 2006-06-24 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel "induction" followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected ... | |||||||||||||
Medical condition: Epithelial ovarian carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020030-25 | Sponsor Protocol Number: APC-10E604 | Start Date*: 2010-08-24 | |||||||||||
Sponsor Name:ACCESS Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase II Trial of ProLindac™ and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer | |||||||||||||
Medical condition: Advanced Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000299-33 | Sponsor Protocol Number: AGO-GYN8 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:AGO Research GmbH | ||||||||||||||||||
Full Title: Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma | ||||||||||||||||||
Medical condition: platinum-refractory ovarian carcinoma or advanced endometrial carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022482-95 | Sponsor Protocol Number: BGOG-ov-5 | Start Date*: 2012-02-07 | |||||||||||||||||||||
Sponsor Name:Belgian Gynaecological Oncolgy Group | |||||||||||||||||||||||
Full Title: BGOG-OV5:Phase II study of weekly Paclitaxel/Carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers. | |||||||||||||||||||||||
Medical condition: recurrence of ovarian, fallopian tube or peritoneal carcinoma, cervical carcinoma or endometrial carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023613-61 | Sponsor Protocol Number: IPR/24 | Start Date*: 2011-06-13 | |||||||||||
Sponsor Name:MOLMED | |||||||||||||
Full Title: NGR018: Randomized phase II study of NGR-hTNF plus pegylated liposomal doxorubicin (PLD) versus PLD in platinum-resistant ovarian cancer | |||||||||||||
Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001323-38 | Sponsor Protocol Number: SOV02 | Start Date*: 2013-08-30 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with rel... | |||||||||||||
Medical condition: epithelial ovarian carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005674-31 | Sponsor Protocol Number: HIPEC_ovaio | Start Date*: 2007-10-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SENESE | |||||||||||||
Full Title: NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGICAL DEBULKING AND INTRAPERITONEAL CHEMOHYPERTHERMIA FOR STAGE III OVARIAN CANCER. A PROSPECTIVE PHASE II STUDY | |||||||||||||
Medical condition: ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.